LBDA Policy on Indirect Rates
Grant proposals to LBDA should not exceed a 10% indirect rate; this is the maximum allowed for the primary applicant organization and any sub-grantees or contractors. (If a grantee has an indirect cost rate lower than 10%, they should not increase the funding to the maximum allowed.) LBDA reserves the right to allow for a higher indirect rate in rare situations as warranted. Written permission from LBDA’s contact person for the grant opportunity is required in advance of submitting a proposal with an indirect rate higher than 10%.
Stay up-to-date on LBD-relevant funding opportunity announcements from LBDA and federal agencies like the National Institutes of Health and Department of Defense.
LBDA New Investigator Pilot Study Award
The Lewy Body Dementia Association (LBDA) New Investigator Pilot Study Award is intended to support young investigators and new investigators in Lewy body dementias (LBD) who have not yet received an R01 award from the National Institutes of Health, to gather preliminary data for projects proposed in future LBD grant applications.
LBDA is seeking proposals for translational or clinical research studies using human subjects, biofluid/tissue samples, or existing clinical data sets to answer questions about LBD diagnosis, clinical management, and well-being of persons with LBD and family caregivers. Basic science applications will not be accepted.
Full details are available on the Request for Proposals.
NINDS Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
The purpose of the NINDS Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (AD/ADRD) Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to support a cohort of new and talented, independent investigators from diverse backgrounds conducting AD/ADRD research. The program is designed to facilitate a timely transition of eligible postdoctoral researchers from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.
Notice of Special Interest (NOSI): Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research
The goal of this Notice of Special Interest (NOSI) is to encourage the use of existing cohorts and datasets for well-focused secondary analyses to investigate novel scientific ideas and/or address clinically related issues on: (1) aging changes influencing health across the lifespan (e.g., Alzheimer’s disease and Alzheimer's disease-related dementias (AD/ADRD)), (2) diseases and disabilities in older persons, and/or (3) the changes in basic biology of aging that underlie these impacts on health (the hallmarks of aging). Activities of high priority include those addressing specific hypotheses in basic biological research, clinical aging research, behavioral or social research, and/or translational geroscience to inform: the design and implementation of future epidemiologic or human intervention studies; interventions in animal models of aging; research on behavioral and social factors over the life course that influence health (e.g., early life adversity); current geriatric practice in maintenance of health, disease management, and prevention of disability; or research testing of possible causal relationships between rates of aging and findings extracted by secondary analysis of the existing data. Existing datasets may also be used to develop and test new mathematical modeling and statistical analytical approaches. Analyses of sex and/or gender differences across health disparity groups (e.g., racial and ethnic groups, socioeconomic status, and sexual and gender minorities) are of high relevance. Use of cohorts that are linked to electronic health record systems and/or Centers for Medicare and Medicaid Services (CMS) administrative data are especially welcome.
Pragmatic Trials for Dementia Care and Caregiver Support (R61/R33 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) will support pragmatic trials within Stage IV of the NIH Stage Model to improve dementia care across multiple dementia care settings that will: (1) be designed to address practical comparative questions faced by Alzheimer’s disease (AD) and AD-related dementia (ADRD) patients, clinicians, and caregivers (both paid and unpaid); (2) include broad and diverse populations; and (3) be conducted in real-world settings with adequate sample size. These trials are intended to produce results that can be directly adopted by healthcare providers, patients, or caregivers for rapid dissemination and implementation. Successful applications will: (1) improve quality of care of persons with dementia; (2) improve quality of life for persons with dementia and their informal caregivers; (3) deliver more patient-focused, cost-effective care across multiple settings; and/or (4) reduce disparities in dementia care.
This FOA will support Stage I or Stage III pilot research to test the feasibility of implementing and integrating interventions (R61 phase) that, if successful, can transition to an R33 phase (Stage IV) for implementation of large pragmatic trials.
The transition from the R61 to the R33 phase of the award will be administratively reviewed and determined by successful completion of the go/no-go criteria that are specified for the R61 phase.
Dementia Care and Caregiver Support Intervention Research (R01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) solicits mechanism-focused dementia care and caregiver support intervention development research at Stages I through V of the NIH Stage Model to address the care needs and promote the health, function, and well-being of persons with Alzheimer’s disease (AD) and Alzheimer’s disease-related dementias (ADRD) and of those providing their care. The NIH Stage Model offers a framework to: (1) support development of efficacious interventions that are defined by their principles; and (2) ensure that these efficacious interventions can be administered in the community or in health systems with fidelity to the intervention’s principles. This includes the development, testing, and validation of scalable training materials and procedures so that these interventions can be delivered with fidelity in community settings or health systems. Settings can include the home, community, or formal care settings, such as nursing homes, assisted living facilities, nursing and rehabilitation centers, hospitals, adult day care, and specialized hospice settings. The overarching purpose of this FOA is to help to lay the groundwork for real-world implementation of AD/ADRD care and caregiving interventions.
Longitudinal Single Cell Characterization of ADRD Postmortem Tissue (R01 Clinical Trial Not Allowed)
The purpose of this funding opportunity is to support projects to identify cellular changes in ADRD post-mortem brain tissue across disease progression. Applicants are encouraged to propose single-nucleus transcriptomic and epigenomic studies that identify changes in neuronal, glial, or vascular cells over multiple ADRD stages, from early to mid-stage. All sequencing data and any available pre-mortem clinical data will be broadly shared with the research community.
NIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
The objectives of the NIH Academic Leadership Career Award (K07) are to increase the pool of individuals with academic and research expertise in a specific area of biomedical research and to enhance the educational or research capacity at the grantee institution. The K07 Leadership Award provides support for senior investigators who are interested in improving the curricula and enhancing the health-related research capacity within an academic institution.
NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 – Independent Clinical Trial Not Allowed)
The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
NIA MSTEM: Advancing Diversity in Aging Research through Undergraduate Education (R25 – Independent Clinical Trial Not Allowed)
The overarching goal of this R25 program is to support educational activities that encourage individuals from diverse backgrounds, including those from groups underrepresented in the biomedical and behavioral sciences, to pursue further studies or careers in research.
NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)
The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.
NINDS Institutional Research Training Program (T32 Clinical Trial Not Allowed)
The objective of the NINDS Institutional Research Training Program is to support outstanding training with the breadth and depth to prepare advanced predoctoral and postdoctoral trainees to become successful scientists in a rapidly evolving research enterprise that is increasingly complex and multidisciplinary.
Notice of Change in Application Types Allowed for PAR-19-071 Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R21 Clinical Trial Not Allowed)
This Notice informs potential applicants that the application types allowed in response to PAR-19-071 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Not Allowed) have been expanded to include Revision and Resubmission applications. This change is effective as of the July 9, 2020 application due date.
Notice of Change in Application Types Allowed for PAR-19-070 Research on Current Topics in Alzheimer’s Disease and Its Related Dementias (R01 Clinical Trial Optional)
This Notice informs potential applicants that the application types allowed in response to PAR-19-070 Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional) have been expanded to include Revision applications. This change is effective as of the July 9, 2020 application due date.
BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)
The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA RFA-NS-19-044 .
BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Required)
The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to enhance workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators from diverse backgrounds in BRAIN Initiative research areas.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to the companion FOA (RFA-NS-19-043)
Jointly Sponsored Ruth L. Kirschstein National Research Service Award Institutional Predoctoral Training Program in the Neurosciences (T32 Clinical Trial Not Allowed)
The Jointly Sponsored NIH Predoctoral Training Program in the Neurosciences (JSPTPN) is an institutional program that supports broad and fundamental research training in the neurosciences. In addition to a broad education in the neurosciences, a key component will be a curriculum that provides a strong foundation in experimental design, statistical methodology and quantitative reasoning. JSPTPN programs are intended to be 2 years in duration and students may only be appointed to this training grant during the first 2 years of their graduate research training. The primary objective is to prepare students to be outstanding scientists equipped to pursue careers in neuroscience.
Advanced-Stage Development and Utilization of Research Infrastructure for Interdisciplinary Aging Studies (R33 Clinical Trial Optional)
This FOA invites applications that propose to support advanced-stage development and utilization of novel research infrastructure to advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Exploratory/Developmental Grants Phase II mechanism to provide support for expanded activities. Applicants are expected to have an existing research infrastructure developed, either through PA-12-064 or with other NIH or non-NIH support. Through this award, investigators will develop a mature and sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Research Infrastructure Development for Interdisciplinary Aging Studies (R21/R33 – Clinical Trial Optional)
This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. This FOA will use the NIH Phased Innovation Award (R21/R33) mechanism to provide up to 2 years of R21 support for initial developmental activities and up to 3 years of R33 support for expanded activities. Through this award, investigators will develop a sustainable research infrastructure to support projects that address key interdisciplinary aging research questions.
Notice of Special Interest: Administrative Supplements for Research on Sex/Gender Influences (Admin Supp Clinical Trial Optional)
The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting the impact of sex and gender influences in human health and illness. Sex and gender are important considerations in many areas of research, including basic biological, psychological, social, and behavioral studies. With continuous interaction between sex and gender, human health is determined by both biology and expression of gender. The most robust experimental designs include consideration of both sex and gender; therefore, applications proposing to investigate the influence of both sex and gender factors are highly encouraged. The proposed research must address at least one objective from the five strategic goals of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women".
Notice of Special Interest: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)
The Office of Research on Women's Health (ORWH) announces the availability of administrative supplements to support research highlighting health disparities among women in the US who are underrepresented, understudied, and underreported (U3) in biomedical research. The proposed research must address at least one objective from the strategic goals 1, 2, or 3 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women."
Notice of Participation of the National Institute on Aging (NIA) in PAR-19-343 Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent CT Not Allowed)
NIA participates in NIH-wide programs to increase diversity in the research workforce. The goal of this FOA is to help outstanding postdoctoral researchers who are considered under-represented minority in science to transition into independent, tenure-track or equivalent faculty positions. NIA welcomes applications in all fields of aging research, including basic science, diseases and disabling conditions of aging, the social and behavioral consequences of an aging society, and topics in between. A particular priority of NIA at the moment is research on Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD).
Improving Quality of Care and Patient Outcomes During Care Transitions (R01)
This Funding Opportunity Announcement (FOA) invites R01 grant applications for funding health services research that improves the quality of care and patient outcomes during transitions of care. The purpose of this FOA is to support large-scale research projects that rigorously test promising interventions aimed at improving communication and coordination during care transitions.
This FOA is focused on three research areas of interest.
- Care transitions between primary care, acute care, and specialty providers
- Care transitions between different institutional care settings
- Care transitions with a focus on patients, their families and communities
Notice of Special Interest: Alzheimer’s-focused administrative supplements for NIH grants that are not focused on Alzheimer’s disease
The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease and its related dementias (AD/ADRD)—frontotemporal dementia, Lewy body dementia, vascular cognitive impairment with dementia, and multiple etiology dementias—to allow the research to develop such a focus. Active awards with project end dates in FY 2021 or later are eligible.
Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional)
This FOA allows for applications that propose large-scale, complex research projects with multiple highly integrated components focused on a common research question relevant to aging. Such projects will likely involve an integrated multidisciplinary team of investigators within a single institution or a consortium of institutions.
Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Systems Biology (R03 Clinical Trial Not Allowed)
This Small Research Grant Program (R03) will support important and innovative system biology projects in which more scientific insight is needed to improve the prevention, diagnosis, treatment, and care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). The overall goal of this R03 program is (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.
Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Archiving and Leveraging Existing Data Sets for Analyses (R03 Clinical Trial Not Allowed)
This Small Research Grant (R03) will support important and innovative projects to provide needed scientific insight to improve the prevention, diagnosis, treatment, and/or care for individuals with Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Specifically, this FOA will support archiving and leveraging existing data sets for analyses of projects covering a wide array of topics relating to AD/ADRD. The overall goal of this FOA is (i) to encourage the next generation of U.S. researchers to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.
Small Research Grant Program for the Next Generation of Researchers in AD/ADRD Research: Area of Focus Basic Science (R03 Clinical Trials Not Allowed)
This Small Research Grant (R03) will support important and innovative projects focused on basic science approaches to elucidate neurodegenerative mechanisms/pathways of Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD). Proposed projects should ultimately aim to improve the prevention, diagnosis, treatment, and/or care for individuals with AD/ADRD. The program seeks (i) to facilitate the next generation of researchers in the United States to pursue research and academic careers in neuroscience, AD/ADRD, and healthy brain aging and (ii) to stimulate established researchers who are not currently doing AD/ADRD research to perform pilot studies toward developing new, innovative AD/ADRD research programs that leverage and build upon their existing expertise.
Aging Research Dissertation Awards to Increase Diversity (R36 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to provide dissertation awards in all areas of research within NIA’s strategic priorities to increase the diversity of the scientific research workforce engaged in research on aging and aging-related health conditions.
NINDS Ruth L. Kirschstein National Research Service Award (NRSA) for Training of Postdoctoral Fellows (F32 Clinical Trial Not Allowed)
The purpose of this award is to support outstanding scientific training of highly promising postdoctoral candidates with outstanding mentors. Candidates are eligible to apply for support from this program from ~12 months prior to the start of the proposed postdoctoral position to within 12 months after starting in the proposed postdoctoral position. This NINDS F32 seeks to foster early, goal-directed planning and to encourage applications for bold and/or innovative projects by the candidate that have the potential for significant impact. Inclusion of preliminary data is strongly discouraged; rather, this F32 seeks innovative research ideas and thoughtful plans for training and mentorship that will facilitate the development of the postdoctoral fellow into an outstanding scientist.
NINDS Postdoctoral Mentored Career Development Award (K01 No Independent Clinical Trial Allowed)
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.
Social Epigenomics Research Focused on Minority Health and Health Disparities (R01-Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support and accelerate human epigenomic investigations focused on identifying and characterizing the mechanisms by which social experiences at various stages in life, both positive and negative, affect gene function and thereby influence health trajectories or modify disease risk in racial/ethnic minority and other health disparity populations.
NINDS Postdoctoral Mentored Career Development Award (K01 Clinical Trial Required)
The purpose of the NINDS Postdoctoral Mentored Career Development Award is to support the ability of outstanding, mentored postdoctoral researchers to develop a potentially impactful research project with a comprehensive career development plan that will enable them to launch an independent research program.
Notice of Intent to Publish a Funding Opportunity Announcement for Impact of Alcohol on the Onset and Progression of Alzheimer’s Disease and Its Related Dementias (R01 – Clinical Trial Optional)
National Institute on Alcohol Abuse and Alcoholism (NIAAA) in partnership with the National Institute on Aging (NIA) intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications to investigate mechanisms underlying the influence of alcohol on the onset and progression of Alzheimer’s disease and its related dementias.
This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects.
The FOA is expected to be published in Fall 2019 with an expected application due date in Spring 2020.
This FOA will utilize the R01 activity code. Details of the planned FOA are provided below.
Research Supplements to Promote Diversity in Health-Related Research (Admin Supp – Clinical Trial Not Allowed)
Funds are available for administrative supplements to enhance the diversity of the research workforce by recruiting and supporting students, post-doctorates, and eligible investigators from underrepresented backgrounds, including those from groups that have been shown to be nationally underrepresented in health-related research. This supplement opportunity is also available to PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. Administrative supplements must support work within the scope of the original project.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Independent Scientist Award (Parent K02 – Independent Clinical Trial Required)
The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.
Independent Scientist Award (Parent K02 Independent Basic Experimental Studies with Humans Required)
The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three to five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate.
This Parent Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind.
Development of Standard Core Clinical Outcomes Assessments (COAs) and Endpoints (UG3/UH3 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for UG3/UH3 cooperative agreements to support the development of a publicly available core set(s) of COAs and their related endpoints for specific disease indications or for disease impacts that span multiple rare diseases of similar phenotypes.
The standard core set(s) can include different types of COAs (i.e. patient-reported outcome [PRO], clinician-reported outcome [ClinRO], observer-reported outcome [ObsRO], performance outcome [PerfO] instruments) and their related endpoints that assess a minimum list of impacts that matter most to patients, are likely to demonstrate change (including differences in trial arms related to disease burden, treatment burden, and if applicable, physical function) and should be reported in a clinical trial. A standard core set might be relevant across several disease populations or subgroups or be focused on attributes of a specific disease (a disease-specific or generic instrument that can adapted and applied more broadly across disease areas or across age groups).
The UG3/UH3 Phase Innovation Award Cooperative Agreement involves 2 phases. The UG3 phase will provide funding for 1 to 2 years to conduct planning activities. The UH3 phase will provide funding for 3 to 4 years to projects that successfully complete the planning activities and reach the projected milestones set in the UG3 phase.
Notice of Special Interest: Fundamental and Translational Research on Decision Making in Aging and/or Alzheimer’s Disease and Alzheimer’s Disease Related Dementias (AD/ADRD)
This Notice of Special Interest (NOSI) underscores NIA’s continued commitment to research that seeks to better characterize the affective, cognitive, social, and motivational parameters of impaired and intact decision making in adults who are aging normally, as well as in individuals with mild cognitive impairment (MCI), Alzheimer’s disease (AD), and AD-related dementias (ADRD). Research is sought that characterizes the extent to which behavioral, psychological, and neural processes involved in decision making are differentially impacted in normal aging, MCI, and AD/ADRD. Investigations that target the influence of social factors on decision making or other factors that render older adults (with or without cognitive impairment) vulnerable to financial exploitation and other forms of mistreatment and abuse are of particular interest.
This NOSI also encourages preclinical and applied research on decision making that may facilitate the design of decision-supportive interventions for midlife and older adults with and without MCI and AD/ADRD. Specific opportunities include the development of decision-support interventions to leverage cognitive, emotional, social, and motivational strengths of these populations; tools to assess decisional capacities; strategies for simplifying choices and offering better defaults; and the promotion of timely adoption of optimal delegation practices (e.g., power of attorney, living wills, etc.). The use of animal models to explore the neural basis of affective, cognitive, social, and motivational parameters as they relate to age-related changes in decision making is also invited.
NINDS Morris K. Udall Centers of Excellence for Parkinson’s Disease Research (P50 Clinical Trial Optional)
This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson’s Disease Research program. The overarching goal of this program is to support specialized research Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson’s disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Applicants will identify an overall research theme that directly addresses a critical challenge in PD research. The Center theme, proposed research projects, and associated cores will inform the etiology, pathogenesis, or treatment of PD; investigations on related synucleinopathies may be included if such directly address the identified PD research challenge.